blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability

2022.02.11

More...
blank News flashes

News Flashes

New version of the European Patent Register – SPC proceedings information in the Unitary Patent Register.

2024-07-24

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register Resource Book
European Patent Register – pocket guide
FAQ - European Patent Register
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP2705849

EP2705849 - A preparation for use of aspartate for regulating glucose levels in blood [Right-click to bookmark this link]
StatusPatent revoked
Status updated on  30.06.2023
Database last updated on 05.10.2024
FormerThe patent has been granted
Status updated on  02.03.2018
FormerGrant of patent is intended
Status updated on  26.11.2017
FormerExamination is in progress
Status updated on  14.12.2016
Most recent event   Tooltip30.06.2023Revocation of patentpublished on 02.08.2023  [2023/31]
Applicant(s)For all designated states
N.V. Nutricia
Eerste Stationsstraat 186
2712 HM Zoetermeer / NL
[N/P]
Former [2014/11]For all designated states
N.V. Nutricia
Eerste Stationsstraat 186
2712 HM Zoetermeer / NL
Inventor(s)01 / Hageman, Robert Johan Joseph
Hamsterlaan 12
6705 CT Wageningen / NL
 [2014/11]
Representative(s)Nederlandsch Octrooibureau
P.O. Box 29720
2502 LS The Hague / NL
[2014/11]
Application number, filing date13152810.118.07.2005
[2014/11]
Priority number, dateUS20040588793P19.07.2004         Original published format: US 588793 P
EP2004007710019.07.2004         Original published format: EP 04077100
EP2004007735920.08.2004         Original published format: EP 04077359
[2014/11]
Filing languageEN
Procedural languageEN
PublicationType: A2 Application without search report 
No.:EP2705849
Date:12.03.2014
Language:EN
[2014/11]
Type: A3 Search report 
No.:EP2705849
Date:15.10.2014
Language:EN
[2014/42]
Type: B1 Patent specification 
No.:EP2705849
Date:04.04.2018
Language:EN
[2018/14]
Search report(s)(Supplementary) European search report - dispatched on:EP12.09.2014
ClassificationIPC:A61K38/02, A61K31/4188, A61K31/714, A61K36/81, A61K36/889, A61K36/48, A23L33/17, A23L33/18, A23L33/19
[2017/48]
CPC:
A61K31/714 (EP,CN,US); A61K31/198 (RU,US); A23L33/18 (EP,CN,US);
A23L13/424 (EP,CN,US); A23L13/65 (EP,CN,US); A23L23/10 (EP,CN,US);
A23L33/17 (EP,US); A23L33/175 (EP,CN,US); A23L33/185 (EP,CN,US);
A23L33/19 (EP,US); A23L33/40 (EP,CN,US); A61K31/4188 (EP,CN,US);
A61K36/48 (EP,CN,US); A61K36/81 (EP,CN,US); A61K36/899 (EP,CN,US);
A61K38/01 (EP,CN,US); A61K38/02 (EP,CN,US); A61P1/16 (EP);
A61P11/00 (EP); A61P13/12 (EP); A61P15/08 (EP);
A61P19/06 (EP); A61P27/10 (EP); A61P29/00 (EP);
A61P3/00 (EP); A61P3/04 (EP); A61P3/08 (EP);
A61P3/10 (EP); A61P31/00 (EP); A61P37/04 (EP);
A61P5/50 (EP); A61P7/00 (EP); A61P9/00 (EP);
A61P9/10 (EP); A61P9/12 (EP); A23V2002/00 (EP,CN,US);
A61K2300/00 (RU); A61K9/08 (RU); A61K9/10 (RU) (-)
C-Set:
A61K36/48, A61K2300/00 (US,CN,EP);
A61K36/81, A61K2300/00 (US,CN,EP);
A61K36/899, A61K2300/00 (US,CN,EP);
A23V2002/00, A23V2200/328, A23V2250/0636, A23V2250/061, A23V2250/0628, A23V2250/062, A23V2250/5114, A23V2250/608, A23V2250/61, A23V2250/1882, A23V2250/5106, A23V2250/156, A23V2250/15 (US,CN,EP);
A23V2002/00, A23V2200/332, A23V2250/5488, A23V2250/15, A23V2250/61, A23V2250/612, A23V2250/5114, A23V2250/1842, A23V2250/1882, A23V2250/1614, A23V2250/1618, A23V2250/1582, A23V2250/1592, A23V2250/1588, A23V2250/702, A23V2250/712, A23V2250/7046, A23V2250/7052, A23V2250/0644 (CN);
A23V2002/00, A23V2200/332, A23V2250/5488, A23V2250/15, A23V2250/61, A23V2250/612, A23V2250/5114, A23V2250/1842, A23V2250/1882, A23V2250/1614, A23V2250/1618, A23V2250/1582, A23V2250/1592, A23V2250/1588, A23V2250/702, A23V2250/712, A23V2250/7046, A23V2250/7052, A23V2250/7046, A23V2250/0644 (EP,US);
A23V2002/00, A23V2200/332, A23V2250/61, A23V2250/0618, A23V2250/54252, A23V2250/5488, A23V2250/612, A23V2250/5114, A23V2250/1842, A23V2250/156, A23V2250/702, A23V2250/712, A23V2250/7042, A23V2250/7052, A23V2250/72, A23V2250/7046, A23V2250/0644 (CN,EP,US)
(-)
Former IPC [2014/42]A61K38/02, A61K38/16, A61K31/4188, A61K31/714, A61P3/00, A61K38/01, A61K36/48, A61K36/81
Former IPC [2014/11]A61K38/02, A61K38/16, A61K31/4188, A61K31/714, A61P3/00
Designated contracting statesAT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HU,   IE,   IS,   IT,   LI,   LT,   LU,   LV,   MC,   NL,   PL,   PT,   RO,   SE,   SI,   SK,   TR [2014/11]
TitleGerman:Präparat zur Verwendung als Aspartat zur Regulierung des Glucosespiegels im Blut[2014/11]
English:A preparation for use of aspartate for regulating glucose levels in blood[2014/11]
French:Préparation pour utiliser de l'aspartate afin de réguler des taux de glucose dans le sang[2014/11]
Examination procedure28.01.2013Examination requested  [2014/11]
15.04.2015Amendment by applicant (claims and/or description)
21.03.2016Despatch of a communication from the examining division (Time limit: M06)
25.10.2016Despatch of communication that the application is deemed to be withdrawn, reason: reply to the communication from the examining division not received in time
14.12.2016Reply to a communication from the examining division
20.10.2017Cancellation of oral proceeding that was planned for 17.11.2017
17.11.2017Date of oral proceedings (cancelled)
27.11.2017Communication of intention to grant the patent
26.02.2018Fee for grant paid
26.02.2018Fee for publishing/printing paid
26.02.2018Receipt of the translation of the claim(s)
Parent application(s)   TooltipEP05762926.3  / EP1771192
Divisional application(s)The date of the Examining Division's first communication in respect of the earliest application for which a communication has been issued (EP20050762926) is  27.01.2011
Opposition(s)Opponent(s)01  19.12.2018    ADMISSIBLE
Fresenius Kabi Deutschland GmbH
Else-Krömer-Strasse 1
61352 Bad Homburg / DE
Opponent's representative
Fresenius Kabi Deutschland GmbH
Patent Department
Pharmaceuticals Division
Borkenberg 14
61440 Oberursel / DE
 [2019/04]
18.01.2019Invitation to proprietor to file observations on the notice of opposition
28.05.2019Reply of patent proprietor to notice(s) of opposition
12.02.2020Date of oral proceedings
09.03.2020Despatch of minutes of oral proceedings
09.03.2020Despatch of communication that the patent will be revoked
29.09.2022Legal effect of revocation of patent [2023/31]
Appeal following opposition07.05.2020Appeal received No.  T1150/20
17.07.2020Statement of grounds filed
29.09.2022Result of appeal procedure: appeal of the proprietor was rejected
26.06.2023Despatch of the decision of the Board of Appeal
29.09.2022Date of oral proceedings
Request for further processing for:The application is deemed to be withdrawn due to failure to reply to the examination report
14.12.2016Request for further processing filed
14.12.2016Full payment received (date of receipt of payment)
Request granted
02.01.2017Decision despatched
Fees paidRenewal fee
28.01.2013Renewal fee patent year 03
28.01.2013Renewal fee patent year 04
28.01.2013Renewal fee patent year 05
28.01.2013Renewal fee patent year 06
28.01.2013Renewal fee patent year 07
28.01.2013Renewal fee patent year 08
28.06.2013Renewal fee patent year 09
30.06.2014Renewal fee patent year 10
30.06.2015Renewal fee patent year 11
30.06.2016Renewal fee patent year 12
29.06.2017Renewal fee patent year 13
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Lapses during opposition  TooltipHU18.07.2005
AT04.04.2018
CY04.04.2018
CZ04.04.2018
EE04.04.2018
FI04.04.2018
LT04.04.2018
LV04.04.2018
MC04.04.2018
RO04.04.2018
SI04.04.2018
SK04.04.2018
BG04.07.2018
GR05.07.2018
LU18.07.2018
BE31.07.2018
IS04.08.2018
PT06.08.2018
[2020/33]
Former [2020/31]HU18.07.2005
AT04.04.2018
CY04.04.2018
CZ04.04.2018
EE04.04.2018
FI04.04.2018
LT04.04.2018
LV04.04.2018
MC04.04.2018
RO04.04.2018
SI04.04.2018
SK04.04.2018
BG04.07.2018
GR05.07.2018
LU18.07.2018
BE31.07.2018
PT06.08.2018
Former [2020/28]HU18.07.2005
AT04.04.2018
CZ04.04.2018
EE04.04.2018
FI04.04.2018
LT04.04.2018
LV04.04.2018
MC04.04.2018
RO04.04.2018
SI04.04.2018
SK04.04.2018
BG04.07.2018
GR05.07.2018
LU18.07.2018
BE31.07.2018
PT06.08.2018
Former [2019/26]AT04.04.2018
CZ04.04.2018
EE04.04.2018
FI04.04.2018
LT04.04.2018
LV04.04.2018
MC04.04.2018
RO04.04.2018
SI04.04.2018
SK04.04.2018
BG04.07.2018
GR05.07.2018
LU18.07.2018
BE31.07.2018
PT06.08.2018
Former [2019/24]AT04.04.2018
CZ04.04.2018
EE04.04.2018
FI04.04.2018
LT04.04.2018
LV04.04.2018
MC04.04.2018
RO04.04.2018
SK04.04.2018
BG04.07.2018
GR05.07.2018
LU18.07.2018
BE31.07.2018
PT06.08.2018
Former [2019/17]AT04.04.2018
CZ04.04.2018
EE04.04.2018
FI04.04.2018
LT04.04.2018
LV04.04.2018
MC04.04.2018
RO04.04.2018
SK04.04.2018
BG04.07.2018
GR05.07.2018
LU18.07.2018
PT06.08.2018
Former [2019/15]AT04.04.2018
CZ04.04.2018
EE04.04.2018
FI04.04.2018
LT04.04.2018
LV04.04.2018
MC04.04.2018
RO04.04.2018
SK04.04.2018
BG04.07.2018
GR05.07.2018
PT06.08.2018
Former [2019/10]AT04.04.2018
CZ04.04.2018
EE04.04.2018
FI04.04.2018
LT04.04.2018
LV04.04.2018
RO04.04.2018
SK04.04.2018
BG04.07.2018
GR05.07.2018
PT06.08.2018
Former [2019/09]EE04.04.2018
FI04.04.2018
LT04.04.2018
LV04.04.2018
BG04.07.2018
GR05.07.2018
PT06.08.2018
Former [2019/03]FI04.04.2018
LT04.04.2018
LV04.04.2018
BG04.07.2018
GR05.07.2018
PT06.08.2018
Former [2018/52]FI04.04.2018
LT04.04.2018
LV04.04.2018
BG04.07.2018
GR05.07.2018
Former [2018/51]FI04.04.2018
LT04.04.2018
LV04.04.2018
BG04.07.2018
Former [2018/50]FI04.04.2018
LT04.04.2018
BG04.07.2018
Former [2018/47]FI04.04.2018
LT04.04.2018
Documents cited:Search[XY]EP0629350  (SANDOZ NUTRITION LTD [CH]) [X] 1,3,8 * page 9, lines 14-30; claim 15 * [Y] 1-18;
 [Y]US6042834  (BARAKA MOHAMED WASIF [KW]) [Y] 1-18 * claim 1 *;
 [Y]WO0137850  (NESTLE SA [CH], et al) [Y] 1-18 * page 9, lines 29-30; claims 1, 5, 6; page 10, lines 4-12 *;
 [XY]US2003118663  (CHANG CHING-MING [TW]) [X] 1,3 * claims 1-3 * [Y] 1-18;
 [XDY]WO03105882  (NOVARTIS NUTRITION AG [CH], et al) [XD] 1,3,4,7 * claims 1-3 * [Y] 1-18;
 [XDY]US6706697  (MACDONALD BRADLEY T [US]) [XD] 5,7 * abstract; claim 1 * [Y] 1-18;
 [Y]WO2004056207  (UNILEVER NV [NL], et al) [Y] 1-18 * abstract, page 25, lines 15-22, claims *;
 [Y]  - LAVIGNE C ET AL, "COD AND SOY PROTEINS COMPARED WITH CASEIN IMPROVE GLUCOSE TOLERANCEAND INSULIN SENSITIVITY IN RATS", AMERICAN JOURNAL OF PHYSIOLOGY: ENDOCRINOLOGY AND METABOLISM, AMERICAN PHYSIOLOGICAL SOCIETY, BETHESDA, MD, US, (20000101), vol. 278, no. 3 part 1, ISSN 0193-1849, pages E491 - E500, XP000978740 [Y] 1-18 * title and abstract *
by applicantUS1560000
 US5430064
 EP0758852
 EP0957692
 WO03105882
 WO03105605
 US2004043013
 US6706697
 WO2004023891
 US6720312
    - ADV. EXP. MED. BIOL., (1990), vol. 270, pages 205 - 225
OppositionWO9110441
 US6743770
 WO2004056207
    - BRAND-MILLER, J. et al., "Glycemic index and obesity", The American Journal of Clinical Nutrition, (20020000), vol. 76, no. 1, pages 281S - 285S, XP055545837

DOI:   http://dx.doi.org/10.1093/ajcn/76.1.281S
    - DEL CARMEN CRESPILLO et al., "Metabolic effects of an enteral nutrition formula for diabetes: Comparison with standard formulas in patients with type 1 diabetes", Clinical Nutrition, (20031000), vol. 22, no. 5, pages 483 - 487, XP055545839

DOI:   http://dx.doi.org/10.1016/S0261-5614(03)00047-5
    - Anonymous, "Enterale Ernährung Trink- aund Sondennahrrungen Produktkatalog", Fresenius Kabi, (20000000), pages 3 - 63, XP055545842
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.